Aytu BioPharma, Inc. — News

ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026.

zacks.com - 2026-07-20 07:36:09

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

zacks.com - 2026-07-16 05:35:14

DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.

accessnewswire.com - 2026-06-01 16:15:00

DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 9:15 a.m.

accessnewswire.com - 2026-05-18 16:05:00

Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-13 21:30:44

Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.2 per share a year ago.

zacks.com - 2026-05-13 18:36:16

EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates Total net revenue of $12.4 million Adjusted EBITDA1 of $(2.8) million, which includes EXXUA ™ (gepirone) extended-release tablets ( " EXXUA " ) launch investments as the Company enters the over $22 billion United States prescription major depressive disorder ( " MDD " ) market $26.7 million cash balance at March 31, 2026 Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / May 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 third quarter.

accessnewswire.com - 2026-05-13 16:05:00